Development and characterization of supramolecular calcitonin assembly and assessment of its interactions with the bone remodelling process

Manglani, Kapil; Vijayan, Viji; Pathak, Chandramani; Khandelwal, Mayuri; Singh, Parminder; Chellappa, Stalin; Yadav, Vijay K.; Surolia, Avadhesha; Gupta, Sarika

doi:10.1016/j.bone.2019.02.019

Cited by 3 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT was found in birds, mammals, reptiles and fish. Having a higher affinity for the human calcitonin receptor, salmon calcitonin (sCT) has a very high potency (up to 100 times higher than human calcitonin), has stronger analgesic effects (5) and is currently being used for medicinal purposes (6). Salmon calcitonin inhibits osteoclasts and promotes osteoblast-induced bone tissue formation, increases bone mass, reduces the serum calcium concentration, and, by inhibiting the reabsorption process in the nephrons, it promotes renal excretion of calcium, sodium, magnesium, and potassium (7).…”

Section: Calcitoninmentioning

confidence: 99%

“…In animal studies, it was shown that sCT-Mal-Asp6 had a 5.4 times higher absorption in bone minerals, a 3 times higher accumulation in the femur and a prolonged circulation time in comparison with sCT (17). Also, it is worth mentioning that calcitonin molecules have a tendency to associate and fibrilize, leading to a loss of potency (5). However, the tendency of calcitonin to self-associate was used to develop a supramolecular form of calcitonin which was proven to act as a prolonged release both in vitro as well as in vivo studies.…”

Section: Salmon Calcitonin In Co-formulation With 5-cnacmentioning

confidence: 99%

“…However, the tendency of calcitonin to self-associate was used to develop a supramolecular form of calcitonin which was proven to act as a prolonged release both in vitro as well as in vivo studies. Indeed, the Supramolecular Calcitonin Assembly (SCA-I) releases calcitonin for a period of at least 3 weeks (5).…”

Section: Salmon Calcitonin In Co-formulation With 5-cnacmentioning

confidence: 99%

See 2 more Smart Citations

Actualities in Endocrine Pharmacology: Advances in the Development of Oral Formulations for Calcitonin and Semaglutide

Hamza

Şaramet

2020

Acta Endo (Buc)

View full text Add to dashboard Cite

As the medical utility of injectable therapeutic peptides is expanding, so is the challenge of developing technologies that allow the administration of such molecules via alternative routes, considering that chronic patients requiring treatment with parenteral formulations are less adherent and compliant to the therapeutic regimens. Hence, substantial efforts have been made to develop technologies that allow the oral formulation of peptides.Due to their importance in the field of pharmaceutical technology, we describe the latest advancements made in the development of oral salmon calcitonin and oral semaglutide, in co-formulation with absorption enhancers such as 8-[(5-chloro-2-hydroxybenzoyl) amino] octanoic acid (or 5-CNAC) and N-[8-(2-hydroxybenzoyl) amino] caprylate (or SNAC). Oral semaglutide is considered to be a landmark for oral peptide delivery technology, as it is one of the very few successful examples of peptides that can be administered orally. Unlike semaglutide, oral calcitonin is still not approved by the regulatory authorities because it failed to demonstrate the anticipated effects in phase III clinical trials conducted so far. However, the efforts for obtaining an oral form of calcitonin have significantly contributed to the development of technologies that facilitate the absorption of peptide-structure macromolecules.

show abstract

Section: Calcitoninmentioning

confidence: 99%

Section: Salmon Calcitonin In Co-formulation With 5-cnacmentioning

confidence: 99%

Section: Salmon Calcitonin In Co-formulation With 5-cnacmentioning

confidence: 99%

See 1 more Smart Citation

Actualities in Endocrine Pharmacology: Advances in the Development of Oral Formulations for Calcitonin and Semaglutide

Hamza

Şaramet

2020

Acta Endo (Buc)

View full text Add to dashboard Cite

show abstract

“…Therefore, it is important to establish a suitable system for controlled-release of sCT. During the past decades, a variety of materials including nanoparticles, films, and inorganic composites were designed to achieve sustained sCT released. − All the them are efficacious but there are still some concerns, such as biosafety and operative difficulty, needing to be considered.…”

Section: Introductionmentioning

confidence: 99%

Thermosensitive Polysaccharide Hydrogel As a Versatile Platform for Prolonged Salmon Calcitonin Release and Calcium Regulation

Liu

Jin

et al. 2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The common pathological characteristic of osteoporosis and hypercalcemia is the disorder of calcium homeostasis. Currently, salmon calcitonin (sCT), a clinical regenerative medicine, is an attractive chioice to regulate calcium metabolism for alleviation of osteoporosis and hypercalcemia. Unfortunately, serum sCT is quickly cleared in vivo, leading to its short half-life. Here, we designed a versatile hydrogel, based on salmon calcitonin-oxidized calcium alginate (sCT-OCA) conjugate and hydroxypropyl chitin (HPCH). The release profile showed that sCT could be released from HPCH hydrogels loaded with sCT-OCA conjugate (sCT-OCA-HPCH) for at least 28 days with conformation stability. The cellular test demonstrated that the biocompatible sCT-OCA-HPCH, compared with sCT formulation, had capacity in up-regulating alkaline phosphatase activity (∼63% increase) and promoting calcium to deposit into extracellular matrix (∼42% increase). These results indicated that thermosensitive sCT-OCA-HPCH hydrogel herein is a versatile platform for many applications such as calcium metabolism regulation, osteoporosis treatment, and hypercalcemia therapy.

show abstract

Spatiotemporally controlled calcitonin delivery: Long-term and targeted therapy of skeletal diseases

Liu

Xie

et al. 2021

Journal of Controlled Release

View full text Add to dashboard Cite

Development and characterization of supramolecular calcitonin assembly and assessment of its interactions with the bone remodelling process

Cited by 3 publications

References 47 publications

Actualities in Endocrine Pharmacology: Advances in the Development of Oral Formulations for Calcitonin and Semaglutide

Actualities in Endocrine Pharmacology: Advances in the Development of Oral Formulations for Calcitonin and Semaglutide

Thermosensitive Polysaccharide Hydrogel As a Versatile Platform for Prolonged Salmon Calcitonin Release and Calcium Regulation

Spatiotemporally controlled calcitonin delivery: Long-term and targeted therapy of skeletal diseases

Contact Info

Product

Resources

About